News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Zacks Investment Research on MSN9h
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowHims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...
Shares of Hims & Hers Health (NYSE: HIMS) are imploding on Monday, down 32% as of 3:03 p.m. ET. The drop comes as the S&P 500 ...
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its ...
Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...
When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...
Hers provides prescription medication and support for weight loss, hair growth, sexual health, and more. Learn more about this telehealth company.
Renaissance Investment Management, an investment management company, released its Q1 2025 “Small Cap Growth Strategy” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback